4.5 Article

Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry

期刊

MABS
卷 8, 期 1, 页码 49-55

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/19420862.2015.1111498

关键词

bispecific antibody; CrossMab; chain pairing; ESI-QTOF mass spectrometry; knobs-into-holes; quadroma

向作者/读者索取更多资源

The quadroma antibody represents the first attempt to produce a bispecific heterodimeric IgG antibody by somatic fusion of 2 hybridoma cells each expressing monoclonal antibodies with distinctive specificities. However, because of random heavy and light chain pairing, the desired functional bispecific antibody represents only a small fraction of the protein produced. Subsequently, the knobs-into-holes (KiH) approach was developed to enforce correct heavy chain heterodimerization. Assuming equimolar expression of 4 unmodified chains comprising 2 heavy and 2 light chains, the statistical distribution of all paired combinations can be calculated. With equimolar expression as the goal, we transfected HEK cells with 1:1:1:1 plasmid ratios and analyzed the protein A affinity-purified antibodies from the quadroma and KiH approaches qualitatively and quantitatively with regard to the estimated relative amounts of the products using electrospray quadrupole time-of-flight mass spectrometry. Our results show that all expected species are formed, and that, within the methodological limits, the species distribution in the mixtures corresponds approximately to the statistical distribution.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biotechnology & Applied Microbiology

Anti-CD20 treatment for B-cell malignancies: current status and future directions

Christian Klein, Candice Jamois, Tina Nielsen

Summary: The introduction of anti-CD20 monoclonal antibody therapy with rituximab in the 1990s significantly improved outcomes for patients with B-cell malignancies. Novel anti-CD20 antibodies like atumumab, ublituximab, and obinutuzumab have been developed with structural and mechanistic differences from rituximab, showing improved efficacy in clinical trials.

EXPERT OPINION ON BIOLOGICAL THERAPY (2021)

Article Hematology

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody

Christian Augsberger, Gerulf Hanel, Wei Xu, Vesna Pulko, Lydia Jasmin Hanisch, Angelique Augustin, John Challier, Katharina Hunt, Binje Vick, Pier Eduardo Rovatti, Christina Krupka, Maurine Rothe, Anne Schonle, Johannes Sam, Emmanuelle Lezan, Axel Ducret, Daniela Ortiz-Franyuti, Antje-Christine Walz, Jorg Benz, Alexander Bujotzek, Felix S. Lichtenegger, Christian Gassner, Alejandro Carpy, Victor Lyamichev, Jigar Patel, Nikola Konstandin, Antje Tunger, Marc Schmitz, Michael Von Bergwelt-Baildon, Karsten Spiekermann, Luca Vago, Irmela Jeremias, Estelle Marrer-Berger, Pablo Umana, Christian Klein, Marion Subklewe

Summary: The novel T-cell bispecific (TCB) antibody targets intracellular antigens, recognizing multiple leukemia-associated targets. WT1-TCB demonstrates potent killing of AML cells through various methods, with enhanced cytotoxicity when combined with immunomodulatory drugs.
Article Immunology

Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells

Vittoria Massafra, Sofia Tundo, Aline Dietzig, Axel Ducret, Christian Jost, Christian Klein, Roland E. Kontermann, Hendrik Knoetgen, Martin Steegmaier, Andrea Romagnani, Yvonne A. Nagel

Summary: This study explores the potential of targeted protein degradation in tumor cells to enhance T cell effector function, and for the first time investigates the impact of combining a degrader and a TCB in cancer immunotherapy.

JOURNAL OF IMMUNOLOGY (2021)

Article Biology

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

S. Jordan Kerns, Chaitra Belgur, Debora Petropolis, Marianne Kanellias, Riccardo Barrile, Johannes Sam, Tina Weinzierl, Tanja Fauti, Anne Freimoser-Grundschober, Jan Eckmann, Carina Hage, Martina Geiger, Patrick Ray Ng, William Tien-Street, Dimitris Manatakis, Virginie Micallef, Regine Gerard, Michael Bscheider, Ekaterina Breous-Nystrom, Anneliese Schneider, Anna Maria Giusti, Cristina Bertinetti-Lapatki, Heather Shannon Grant, Adrian B. Roth, Geraldine A. Hamilton, Thomas Singer, Katia Karalis, Annie Moisan, Peter Bruenker, Christian Klein, Marina Bacac, Nikolce Gjorevski, Lauriane Cabon

Summary: This study demonstrated the unprecedented capability of two human Organs-on-Chips in evaluating the safety profile of T-cell bispecific antibodies targeting tumor antigens, predicting TCB safety liabilities based on target expression and antibody affinity. These novel tools broaden research options for understanding engineered therapeutic antibodies and assessing safety in tissues susceptible to adverse events.
Article Oncology

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies

Gabrielle Leclercq, Helene Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch, Antje-Christine Walz, Vesna Pulko, Johannes Sam, John Challier, Cristiano Ferlini, Alex Odermatt, Pablo Umana, Marina Bacac, Christian Klein

Summary: The study demonstrates that dasatinib can effectively serve as a pharmacological on/off switch to mitigate off-tumor toxicities or CRS induced by T cell bispecific antibodies. By providing pharmacologically relevant doses, dasatinib can regulate T cell activation, cell killing, and cytokine release triggered by T cell engagers.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Article Oncology

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia

Raquel Delgado, Karoline Kielbassa, Johanna ter Burg, Christian Klein, Christine Trumpfheller, Koen de Heer, Arnon P. Kater, Eric Eldering

Summary: The study revealed that selicrelumab can enhance the sensitivity of CLL cells to CD20 monoclonal antibodies, despite its minimal pro-survival effect. Combining selicrelumab with anti-CD20 antibodies may be a promising therapeutic strategy for CLL.

CANCERS (2021)

Article Biochemistry & Molecular Biology

Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies

Steffen Dickopf, Can Buldun, Vedran Vasic, Guy Georges, Carina Hage, Klaus Mayer, Matthias Forster, Uwe Wessels, Kay-Gunnar Stubenrauch, Jorg Benz, Andreas Ehler, Matthias E. Lauer, Philippe Ringler, Sebastian Kobold, Stefan Endres, Christian Klein, Ulrich Brinkmann

Summary: The field of multi-specific antibody derivatives is rapidly growing, with domain exchange reactions being able to generate hybrid antibodies under physiological conditions for potential therapeutic applications.

BIOLOGICAL CHEMISTRY (2022)

Article Medicine, Research & Experimental

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Alvaro Teijeira, Itziar Migueliz, Saray Garasa, Vaios Karanikas, Carlos Luri, Asunta Cirella, Irene Olivera, Marta Canamero, Maite Alvarez, Maria C. Ochoa, Ana Rouzaut, Maria E. Rodriguez-Ruiz, Miguel F. Sanmamed, Christian Klein, Pablo Umana, Mariano Ponz, Marina Bacac, Ignacio Melero

Summary: In this study, the performance of the CEA-CD3 T cell bispecific antibody cibisatamab in three-dimensional tumor organoids cocultured with T cells was investigated using time-lapse confocal microscopy. The results showed that the killing of tumor cells was dependent on the levels of surface CEA expression, and the higher affinity CEACAM5-CD3 bispecific antibody remained active on low CEA expressing organoids. Additionally, the coculture of tumor organoids, autologous fibroblasts, and T cells demonstrated a costimulatory effect of anti-FAP-4-1BBL antibody, leading to enhanced tumor cell killing.

THERANOSTICS (2022)

Article Oncology

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils

Gabrielle Leclercq, Llucia Alberti Servera, Sabrina Danilin, John Challier, Nathalie Steinhoff, Claudia Bossen, Alex Odermatt, Valeria Nicolini, Pablo Umana, Christian Klein, Marina Bacac, Anna-Maria Giusti, Anneliese Schneider, Helene Haegel

Summary: This study investigated the biological mechanisms of cytokine release after treatment with T cell bispecific antibodies (TCBs) and identified T cells as the triggers and monocytes and neutrophils as the amplifiers of the cytokine cascade. Moreover, it demonstrated the contribution of neutrophils to TCB-mediated cytokine release using single-cell RNA sequencing.

ONCOIMMUNOLOGY (2022)

Article Oncology

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy

Gabrielle Leclercq, Helene Haegel, Alberto Toso, Tina Zimmermann, Luke Green, Nathalie Steinhoff, Johannes Sam, Vesna Pulko, Anneliese Schneider, Anna Maria Giusti, John Challier, Anne Freimoser-Grundschober, Laurent Lariviere, Alex Odermatt, Martin Stern, Pablo Umana, Marina Bacac, Christian Klein

Summary: This study aimed to identify small molecules that can reduce cytokine release while maintaining T cell-mediated tumor killing. By screening a library of FDA-approved kinase inhibitors, mTOR, JAK, and Src kinase inhibitors were found to modulate cytokine release. Further in vitro and in vivo experiments confirmed these findings and supported the evaluation of these inhibitors as a treatment to prevent cytokine release syndrome (CRS).

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Review Oncology

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors

Gabrielle Leclercq, Nathalie Steinhoff, Helene Haegel, Donata De Marco, Marina Bacac, Christian Klein

Summary: T cell engaging therapies redirect T cells towards tumor cells, leading to cytotoxicity. However, this can trigger a release of pro-inflammatory cytokines causing Cytokine Release Syndrome (CRS), which remains a major safety concern. Mitigation strategies are necessary to reduce cytokine release while maintaining efficacy. Tyrosine kinase inhibitors are emerging as a potential strategy for managing CRS symptoms.

ONCOIMMUNOLOGY (2022)

Review Oncology

Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review

Andrew Davies, Arnon P. Kater, Jeff P. Sharman, Stephan Stilgenbauer, Umberto Vitolo, Christian Klein, Joana Parreira, Gilles Salles

Summary: The type II anti-CD20 antibody obinutuzumab has shown improved efficacy compared to rituximab in the treatment of indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). Ongoing research is focusing on biomarkers and developing chemotherapy-free regimens involving obinutuzumab.

FUTURE ONCOLOGY (2022)

Article Cell Biology

Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies

Ester Fagnano, Swati Pendharkar, Madyson Colton, Philip N. Jones, Marta Crespi Sallan, Tetyana Klymenko, Andrejs Braun, Christian Klein, Jamie Honeychurch, Eleanor J. Cheadle, Timothy M. Illidge

Summary: This study showed that contact between tumor cells and stromal cells inhibits the effector functions of Obinutuzumab, highlighting the potential for improved therapies targeting the microenvironment to enhance patient outcomes in B-cell malignancies.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)

Review Medicine, Research & Experimental

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

Marlena Surowka, Wolfgang Schaefer, Christian Klein

Summary: CrossMab technology, introduced in 2011, enables correct light-chain and heavy-chain association in bispecific antibodies and has become one of the most mature and widely applied technologies in the field. Multiple bispecific antibodies based on CrossMab technology have entered clinical trials, demonstrating potential therapeutic value in different disease settings.
Meeting Abstract Oncology

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.

Stephan Wullschleger, Melanie Tichet, Laura Codarri-Deak, Pablo Umana, Christian Klein, Douglas Hanahan

CANCER RESEARCH (2021)

暂无数据